Review decision – September 2019
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA410; Talimogene laherparepvec for treating unresectable metastatic melanoma.
Talimogene laherparepvec is recommended for people with melanoma for whom immunotherapy is not suitable or otherwise contraindicated. No new evidence has been published on talimogene laherparepvec monotherapy, and there is no reason to change the recommendations.
Consequently, TA410 will move to the ‘static list’ of technology appraisals. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: 27 September 2019